A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Gemtuzumab ozogamicin (Primary) ; Tremtelectogene empogeditemcel (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; First in man; Proof of concept
Sponsors Vor Biopharma

09 Dec 2024 According to a Vor Biopharma media release, the Company had the opportunity to interact with the FDA regarding data from the trem-cel + Mylotarg study.
09 Dec 2024 According to a Vor Biopharma media release, the Company were presented data in a poster at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 8th.
09 Dec 2024 Results presented in a Vor Biopharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com